アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場 – 2030年までの業界動向と予測

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場の分析と洞察

血液がんは、ここ数十年、世界中で最も一般的ながんです。がんの発生率は、男女ともに上昇傾向にあります。男性の方が女性よりわずかに多く発生します。急性リンパ性白血病（ALL）は、米国のリンパ系腫瘍の約2％を占めています。患者は通常、骨髄が腫瘍に置き換わることによって、貧血、血小板減少症、好中球減少症に関連する症状を呈します。白血病の診断治療における激しい競争と、世界中で診断の改善が求められていることから、この分野ではさまざまなサービスの需要が高まっています。さまざまな企業が、アジア太平洋の急性リンパ性/リンパ芽球性白血病（ALL）診断市場に対する世界的な需要の高まりに対応するために、多数の診断製品を発売しています。

しかし、白血病の治療には、治療法、医薬品などを含めて高額な費用がかかることが、最も重要な要因の 1 つです。その結果、長期的には市場の成長が阻害される可能性があります。診断製品のコストは、白血病診断装置ベンダーにとって課題となる可能性のある要素の 1 つです。

データブリッジ市場調査は、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、予測期間中に8.1％のCAGRで成長し、2030年までに3億3,205万米ドルに達すると予測しています。アジア太平洋地域で白血病診断の需要が急増しているため、製品タイプが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

Market Definition

Acute lymphocytic leukemia (ALL) is a malignancy of B or T-lymphoblasts characterized by uncontrolled proliferation of abnormal, immature lymphocytes and their progenitors, which ultimately leads to the replacement of bone marrow elements and other lymphoid organs resulting in a characteristic disease pattern. B-cells are a specific type of lymph cell that affect a body's immune system. Two types of B-cell leukemia are prolymphocytic leukemia (PLL) and Hairy Cell Leukemia (HCL). Symptoms include fatigue, easy or spontaneous bruising and bleeding, and infections. Additionally, B-symptoms, such as fever, night sweats, and unintentional weight loss, are often present but may be mild, and hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central Nervous System (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure. T-cell lymphoblastic leukemia is most common among children aged over five years. The increasing cases of cancer worldwide and the rising prevalence of lymphoblastic leukemia are expected to drive segmental T-cell acute lymphoblastic leukemia market growth. These white blood cell acutely influences white platelets called T- lymphocytes. The Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market is expected to show significant growth due to the rising prevalence of T-cell acute lymphoblastic leukemia, research and development activities, and high healthcare expenditure.

Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Growing prevalence of leukemia cancer

All ages can be affected by leukemia. Leukemia can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. Acute lymphoblastic leukemia has the highest emergency presenting rates of any cancer kind, with a leukemia emergency diagnostic rate of 37% on average.

The most frequent form of juvenile cancer is acute lymphoblastic leukemia, a heterogeneous illness defined by unchecked lymphoid progenitor proliferation that typically begins in utero. Although the prevalence of ALL has been rising significantly in recent decades, there is still no apparent cause for this development. Rising maternal obesity rates may be partially responsible for the rise in ALL prevalence.

Thus, acute leukemia incidence has been rising Asia-Pacificly due to various risk factors, becoming a significant socio-economic issue. This is expected to act as a driver in the Asia-Pacific acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

•  Novel technological advancements in leukemia diagnostics

The most common form of blood cancer, acute lymphoblastic leukemia (ALL), is also one of the main causes of death. The blood is invaded by this form of cancer, which then spreads to nearby organs and bodily systems. Specialists must manually diagnose cancer and non-cancer cells by examining cell images under a microscope and providing labels through annotation. However, this hand microscopic examination is time-consuming and could give an incorrect diagnosis.

The risk of prescribing the incorrect drugs was then reduced using computerized software. The creation of an automatic and reliable classification system became vital to stop the leukemia disease's devastating effects. Multiple segmentation techniques constituted the foundation of the existing leukemia classification algorithms.

The manual examination of stained blood smear microscopy pictures used in current practice for the initial diagnosis of ALL is time-consuming and prone to error. A potent tool for aiding doctors in making medical decisions has emerged: deep learning-based human-centric biomedical diagnostics. Various computer-aided diagnostic techniques have been created to recognize ALL blood pictures automatically.

The development of several new diagnostic methods will increase the market's growth as many new and advanced products are launched. Hence, it is expected to create demand for acute leukemic cancer diagnosis in the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Restraint

• Late diagnosis and poor prognosis of leukemia

Cancer is the leading cause of death Asia-Pacificly. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, patient delays may result. The main cause of delayed presentation is thought to be a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.

The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Asia-Pacific acute lymphocytic\lymphoblastic leukemia (ALL) diagnostics market.

Opportunities

• Increase in diagnostic products for leukemia

A blood-forming tissue cancer impairs the body's capability to combat infection. Bone marrow is one of the blood-forming tissues that can develop leukemia. Numerous varieties include chronic lymphocytic leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Many patients with leukemia that grow slowly do not exhibit any symptoms. Fatigue, weight loss, recurrent infections, and easy bruising or bleeding are all possible symptoms of leukemia that grow quickly. Treatment results vary greatly. Treatment for leukemia with a slow growth rate may involve monitoring. Chemotherapy for malignant leukemia is occasionally combined with radiation therapy and stem cell transplant.

Thus, the rise in diagnostic product approvals has led to an increased number of highly efficient products in the market for leukemia diagnosis treatment. This is expected to create an opportunity for the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

• Government initiatives toward cancer diagnostics

The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Leukemia has increased very rapidly in individuals in past decades. Leukemia is the most prevalent cancer, with 60,650 new cases in 2022, according to cancer.gov.

There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. For this reason, government initiatives towards cancer diagnostics are acting as an opportunity for growing the demand of the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Challenge

• Increased cost, safety, and convenience issue

Leukemia is fatal cancer, and the diagnosis process of leukemia also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat Asia-Pacificly is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.

Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to an increase in the use of reconstructed diagnostic imaging due to high expenditures and financial restrictions. Due to the increasing demand for diagnostic imaging operations in these nations, hospitals that can't afford to buy new, cutting-edge imaging systems instead choose to employ refurbished imaging equipment, which could have long-term negative effects.

Henceforth, the current leukemia diagnosis process has safety, cost, and convenience issues, which are expected to challenge the growth of the Asia-Pacific acute lymphocytic/lymphoblastic leukemia (ALL) diagnostics market.

Post-COVID-19 Impact on Asia-Pacific Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Diagnostics Market

The cancer diagnostics market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.

Manufacturers make various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results in the cancer diagnostics market.

Recent Developments

• In October 2022, Thermo Fisher Scientific Inc. announced that it had entered into a definitive agreement to acquire The Binding Site Group, a Asia-Pacific leader in specialty diagnostics. The acquisition will help in the development of the specialty diagnostics segment.
• In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場の範囲

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場は、 製品タイプ、検査タイプ、がんタイプ、年齢層、性別、エンドユーザー、流通チャネルに分類されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを判断するのに役立ちます。

製品タイプ

• 楽器
• 消耗品とアクセサリー

製品タイプに基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、機器、消耗品、付属品に分類されます。

テストの種類

• 画像検査
• 生検
• 血液検査
• その他

検査の種類に基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、画像検査、生検、血液検査、その他に分類されます。

がんの種類

•  B細胞リンパ芽球性白血病/リンパ腫
• T細胞リンパ芽球性白血病

がんの種類に基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、B細胞リンパ芽球性白血病/リンパ腫とT細胞リンパ芽球性白血病に分類されます。

年齢別

• 21歳未満
• 21-29
• 30-65
• 65歳以上

年齢層に基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、21歳未満、21〜29歳、30〜65歳、65歳以上に分類されます。

性別別

• 男
• 女性

性別に基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は男性と女性に分類されます。

エンドユーザー別

• 病院
• 関連ラボ
• 独立診断研究所
• 画像診断センター
• がん研究機関
• その他

エンドユーザーに基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、病院、関連ラボ、独立した診断ラボ、診断画像センター、がん研究機関、その他に分類されます。

流通チャネル別

• 直接入札
• 小売販売

流通チャネルに基づいて、アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場は、直接入札と小売販売に分類されます。

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場の地域分析/洞察

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場が分析され、国、製品タイプ、検査タイプ、がんの種類、年齢層、性別、エンドユーザー、流通チャネル別に市場規模の情報が提供されます。

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場に含まれる国としては、中国、日本、インド、韓国、シンガポール、ベトナム、タイ、マレーシア、オーストラリア、フィリピン、インドネシア、その他のアジア太平洋地域が挙げられます。

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場では、白血病診断における新たな技術の進歩により、中国が成長すると予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と国内規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境とアジア太平洋の急性リンパ性/リンパ芽球性白血病（ALL）診断市場シェア分析

アジア太平洋の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場の競争状況では、競合他社の詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、および技術ライフライン曲線があります。提供されている上記のデータ ポイントは、アジア太平洋の急性リンパ性/リンパ芽球性白血病 (ALL) 診断市場への会社の重点にのみ関連しています。

アジア太平洋地域の急性リンパ性/リンパ芽球性白血病（ALL）診断市場で活動している主要企業には、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific, Inc.、QIAGEN、Abbott、Merck KGaA、Siemens Medical Solutions USA, Inc.、Hologic, Inc.、Agilent Technologies, Inc.、DiaSorin SpA、Illumina, Inc.、Myriad Genetics, Inc.、bioMérieux SA、Quest Diagnostics Incorporated、Bio-Rad Laboratories, Inc.、Koninklijke Philips NV、BD、Exact Sciences Corporation、Time Medical Holding、PlexBio、MinFound Medical Systems Co., Ltd、Medonica Co. LTD などがあります。

SKU-69601